This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Momenta Pharmaceuticals, Inc.(MNTA)
Bank of America Merrill Lynch 2012 Health Care Conference Call
May 16, 2012 8:00 pm ET
Richard P. Shea – Senior Vice President and Chief Financial Officer
Sumant S. Kulkarni – Bank America/Merrill Lynch
PresentationSumant S. Kulkarni – Bank America/Merrill Lynch
Good afternoon everyone. I’m very pleased to have Momenta here with us today. Thanks for taking the time and sticking around for this last presentation it’s going to be an interesting one because this is a really interesting company in the generic pharmaceuticals space. For those of you who that don’t know me I’m Sumant Kulkarni and I’m part of the specialty pharmaceuticals in U.S. major pharmaceuticals team here at the firm. So we have Rick Shea, who is the CFO and who is back with us this year and Lora Pike, who is with us for the first time this year is the IR for Momenta. Thanks.
Richard P. Shea
Thanks very much Sumant. I will draw your attention to our risk factors particularly as included within our SEC filings. Momenta was founded and built based on analytical technologies for deconvolution and characterizing complex mixture drugs and these complex mixture drugs include polysaccharides heparin based drugs, polypeptides as well as biologics which includes glycosylated proteins and antibodies and technology that we use is by understanding the drug and understanding the chemical structure of the drug we are able to analyze and recreate exact copies of a complex drug in order to make a generic version or a biosimilar version. But we are also able to do structure activity relationship analysis and whether to understand how to engineer novel drugs based on this technology.